Combination therapy of biologic and non-biologic systemic agents in psoriasis: A narrative review of real-world evidence and clinical positioning
Abstract
Biologic therapies have substantially improved outcomes in moderate-to-severe psoriasis; however, in real-world practice, secondary loss of efficacy - often driven by immunogenicity and ultimately reflected in reduced treatment persistence - remains an important clinical challenge. Although biologic-disease-modifying antirheumatic drug (DMARD) or non-biologic systemic agents combination therapy is not a standard treatment strategy, it is occasionally used in clinical practice for patients with partial response or disease instability. This narrative review summarizes real-world observational evidence on biologic and non-biologic systemic agents combination therapy in adult psoriasis. Across seven real-world studies involving 237 patients, methotrexate was the most frequently used concomitant DMARD, followed by cyclosporine and apremilast, predominantly as add-on or rescue therapy. Combination treatment was generally associated with modest improvement in skin outcomes, maintained treatment persistence, and acceptable safety profiles, while high-level clearance responses were uncommon. Evidence supporting combinations with acitretin, sulfasalazine, or deucravacitinib remains limited or absent. Overall, biologic and non-biologic systemic agents combination therapy may offer additional benefit in specific clinical contexts, supporting its consideration as an individualized treatment option rather than a universal escalation strategy.